Compare Abeona Therapeutics Inc (ABEO) vs CSX Corporation (CSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs CSX Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while CSX Corporation trades at $48.67 (market cap $90.14B). The key difference: CSX Corporation is far larger — about 241.5× Abeona Therapeutics Inc's market cap, and CSX Corporation pays a 1.15% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CSX | |
|---|---|---|
Market Cap | $373.32M | $90.14B |
Sector | Health | Industrials |
52-Week High | $7.23 | $48.89 |
52-Week Low | $4.17 | $32.05 |
Enterprise Value | $228.22M | $108.37B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CSX trades at $48.51, down 0.78% on the day, with a bullish technical outlook from moving averages but neutral oscillators. The company reported a net income margin of 21.55% for 2025, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analyst consensus is a Buy with a $46.83 price target, and the stock has seen positive news coverage highlighting operational improvements and a recent dividend declaration.
The outlook for CSX is cautiously optimistic, supported by strong profitability metrics and analyst upgrades, but tempered by declining revenue trends and high valuation multiples. Key risks include freight demand volatility and competitive pressures, while institutional sentiment remains positive with a majority of analysts recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
